Timeline

Voting rights breakdown

Declared beneficial owners · 21

A single, collectively filed disclosure: the voting-rights rate applies to the whole group, not to each person.

• Aravis Venture I LP6.3%
• Astellas Venture Capital, LLC6.3%
• Auriga Ventures III6.3%
• Baltisches Haus Limited6.3%
• BioMedInvest II LP6.3%
• Dansk Innovationsinvestering P/S c/o Maj Invest A/S6.3%
• Entrepreneurs Fund General Partners Limited6.3%
• Evolva Holding SA6.3%
• Mona Lisa Capital SA6.3%
• Novartis Bioventures Ltd6.3%
• Renaisance PME fondation suisse d investissement / Mona Lisa6.3%
• Sunstone Life Science Ventures Fund I K/S6.3%
• Symbion Capital I A/S6.3%
• Wellington Partners Ventures III Life Science Fund L.P6.3%
• Wellington Partners Ventures III Life Science Network Fund L6.3%
• Neil Goldsmith6.3%
• Alexandra SantAna Sørensen6.3%
• Pascal Longchamp6.3%
• Jakob Dynnes Hansen6.3%
• Jutta Heim6.3%
• PM Murali6.3%

Notice details

Beneficial owner

Aravis Venture I LP

On December 13, 2010 the members of the group (the Sale Group) have agreed to execute a coordinated sale by way of block trades and sales on the market of the SIX Swiss Exchange Ltd. with regard to 10% of their aggregate holdings (i.e. 12,380,977 shares) up to and including May 23, 2011. On 17 May 2011, the Sale Group has agreed to extend the coordinated sale by way of block trades and sales on the market of the SIX Swiss Exchange Ltd with regard to the remaining 8,794,076 shares. This extension is of unlimited nature, i.e. until terminated. The termination of the group will be disclosed. Additional information can be downloaded from the Evolva website: www.evolva.com/press-investors/investors/disclosure-shareholdings